$15.41
22.11% yesterday
Nasdaq, Jan 06, 10:17 pm CET
ISIN
US09077V1008
Symbol
BIOA

BioAge Labs Stock price

$15.41
+3.58 30.26% 1M
+11.23 268.66% 6M
+2.18 16.48% YTD
+10.02 185.90% 1Y
-2.59 14.39% 3Y
-2.59 14.39% 5Y
-2.59 14.39% 10Y
-2.59 14.39% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
+2.79 22.11%
ISIN
US09077V1008
Symbol
BIOA
Industry

Key metrics

Basic
Market capitalization
$552.5m
Enterprise Value
$270.9m
Net debt
positive
Cash
$285.8m
Shares outstanding
35.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
93.3 | 76.8
EV/Sales
45.8 | 37.6
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
90.2%
Return on Equity
-22.0%
ROCE
-32.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.9m | $7.2m
EBITDA
$-89.5m | $-91.3m
EBIT
$-89.7m | $-91.8m
Net Income
$-75.8m | $-84.1m
Free Cash Flow
$-59.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-1.7% | -17.1%
EBIT
-1.7% | -17.4%
Net Income
24.8% | -18.3%
Free Cash Flow
6.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,513.1% | -1,269.4%
EBIT
-1,516.3%
Net
-1,280.9% | -1,168.7%
Free Cash Flow
-999.6%
More
EPS
$-2.1
FCF per Share
$-1.6
Short interest
1.8%
Employees
-
Rev per Employee
-
Show more

Is BioAge Labs a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

BioAge Labs Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a BioAge Labs forecast:

1x Buy
11%
4x Hold
44%
4x Sell
44%

Analyst Opinions

9 Analysts have issued a BioAge Labs forecast:

Buy
11%
Hold
44%
Sell
44%

Financial data from BioAge Labs

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5.92 5.92
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
12% 12%
455%
- Research and Development Expense 69 69
7% 7%
1,160%
-90 -90
2% 2%
-1,512%
- Depreciation and Amortization 0.19 0.19
10% 10%
3%
EBIT (Operating Income) EBIT -90 -90
2% 2%
-1,516%
Net Profit -76 -76
25% 25%
-1,280%

In millions USD.

Don't miss a Thing! We will send you all news about BioAge Labs directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. The company is headquartered in Emeryville, California and currently employs 62 full-time employees. The company went IPO on 2024-09-26. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Head office United States
Website bioagelabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today